Nike is Back in the Race
Why Nike stock rallied after its latest earnings report.
Home Depot buying GMS for $5.5 billion.
Will F1: the Movie drive Apple's stock?
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy.
A full transcript is below.
Before you buy stock in Nike, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nike wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!*
Now, it's worth noting Stock Advisor's total average return is 1,050% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
This podcast was recorded on June 30, 2025.
Andy Cross: Nike is back in the race, Motley Fool Money starts now. Welcome to Motley Fool Money. I'm Andy Cross, joined here by Motley Fool contributor Jason Hall. On the docket today are earnings from Nike, Jason, Home Depot's latest acquisition, and we're lifting the hood on F1 The Movie and what it means for Apple. Jason, let's dive right into it. Nike's fourth quarter earnings were last week. The stock jumped 15% on that Friday after the footwear giant expressed confidence that it's turn around, that Elliott Hill, the CEO, who joined eight months ago, is moving along even though the quarter continues to show that challenge. Jason, is that investor enthusiasm warranted?
Jason Hall: Honestly, I think I would have framed it in a different way. The stock jumped on earnings, but if you look over the past five years, Nike stock has fallen after earnings far more often than it's gone up. The stock's still down a quarter from where it was five years ago, and it's down almost 60% from the high. I don't think this is about enthusiasm as much as it is investors reframing and resetting their expectations, and seeing the company with those lower expectations and the fact that this turnaround is going to take a while, there are some signs that it's starting to work.
Andy Cross: Jason, the sales down 12% year over year, still ahead of some estimates, earnings per share were down 86%, beating consensus a little bit. The big thing was on the gross margins down 440 basis points to 40%. If you look a few quarters ago, gross margins were around 45%. We're seeing this impact on the inventories for Nike. I think that's a big story that investors are focused on with this turnaround.
Jason Hall: There's no doubt about it. One of the big parts of the Nike struggles over the past few years is trying to figure out their go-to-market strategy. They heavily prioritize their own digital channels, alienated a lot of the wholesale market, which is the retail channel, and they're having to come back around to that, a little bit with hat in hand, and they're starting to see a little bit of signs of improvement. We know that Dick's big acquisition that they're working on. With Foot Locker, that hopefully is going to be positive for Nike. Maybe the big thing is the e-commerce presence of finally accepting that they need to be part of the Amazon ecosystem. There's some limited release products that are going to be showing up there this fall. Those are things that the market wants to see. The company has to embrace customers wherever they are, and then try to have a little bit of exclusivity with its own e-commerce. I think that that's a successful formula. I think the market agrees too.
Andy Cross: One thing, Jason, about their five "Win Now" principles, which is they're like, right now we are focused on Elliott Hill. Again, coming back in, he's a long term veteran, joined about eight months or so ago, trying to get the branding back for Nike Build Back, the Nike goodwill, focus on things like culture, product, marketing, the ground game being, as you were saying, where customers are on the ground, focusing in key sports, rightsizing those important brands that have those legacy brands. What I really like is they're restructuring the team and the whole focus back around sport chase, and they're focused back on cross-functional teams focused on specific sports. I think that is a really important focus for this Nike turnaround. While we're not seeing it in the earnings or the performance right now, I think that, what I consider enthusiasm, and I think the stock is actually pretty attractive here, even after that jump, I think the enthusiasm is warranted because of the way that Elliott Hill is going about refocusing the Nike brand, and importantly the Nike culture.
Jason Hall: I think that's right. Focusing on the brand, I'll start there. I've talked to a ton of people across sports that say that a lot of Nike's success right now is selling things that they were selling 30 years ago. Obviously, it's not exactly the truth, but it feels that way. They've certainly lost their innovative edge against on running other brands that have taken share, and having that hyper focus back on the products for that individual performance for that particular sport, I think is something that Nike has not done as well with. If they can show that and say, "Look, we can still innovate. We can come out with products that are going to be better, not just the fit, but the performance," that's where Nike can reestablish itself as a leader.
Andy Cross: It's interesting. They're going to do a little bit of surgical pricing, they mentioned, tied to Amazon a little bit later this fall. They do have a big tariff impact of about $1 billion because of all the sourcing they do overseas. Although they're trying to change that, they're going to move a little bit away from China, and they think as a percentage of sales that will drop going forward, but they do still have those impacts, and it's going to show up in the gross margin over the next quarter or two. But the expectations, Jason, is that it's going to improve throughout the year.
Jason Hall: That's right. Andy, everybody in apparel and footwear is dealing with the impact of tariffs, the potential impact. That story is going to continue to be part of the background for some time to come. I'm taking all of that with a grain of salt, that I think the supply chain is probably going to look more like it did five years ago than change going forward, but the company does have to take some financial steps to make sure it's prepared for whatever happens there.
Andy Cross: Jason, how about the stock here, about $71, $106 billion market cap. You get a little dividend, 2.2%. Hopefully, bottomy on the earnings side that you look going forward are going to be meaningfully higher. Do you find this stock attractive?
Jason Hall: I do. I did a video for the Motley Fools website a couple of weeks ago, and I said that there were signs that the turnaround was working. We'd get more information once earnings came out, and they just did. Again, probably things are going to maybe take a little longer than we expected, but I think even with the stock up from where it was a couple of weeks ago, I think there are definitely signs that it's worth maybe starting a position, following things out in. It's not super cheap right now, but I think if the trend continues under Elliott's leadership, then this is going to work out to be a good price.
Andy Cross: Certainly not on current earnings, but hopefully on the future earnings.
Jason Hall: Exactly.
Andy Cross: In agreement there, I think Nike looks attractive here. After the break, Home Depot go shopping. You're listening to Motley Fool Money. Specialty building products distributor GMS is up about 11% today after announcing that Home Depot had won the bidding battle to acquire the company for 5.5 billion. Jason, GMS has been on the auction block probably for the past month or so since QXO, another building products supplier and technology company, put out an offer for about $95 per share. Home Depot's paying $110 per share. Did Home Depot win the acquisition battle here but lose the capital allocation war?
Jason Hall: I think that's the question that I have. Home Depot, about a year ago, got into the distribution business that I think dropped $18 billion to buy a distributor, and part of the long term strategy was, look, this is an area we can consolidate, and these are builders and customers that are not coming into Home Depot no matter how well we work with them. It's big distribution. The plan had been to do that. Now, at the same time, you mentioned QXO, so that's Brad Jacobs. Brad Jacobs is the M&A master. This is somebody that has build a career on multibagger businesses, that he's made a lot of people a lot of money finding industries that are ripe for consolidation, that are low tech, that a layer of technology can make a tremendous amount better. QXO fired the opening salvo, as you said, with an unsolicited offer to buy GMS. Then Home Depot, we hear is getting involved. The question that I'm going to continue to ponder is, did Home Depot win it, or did Brad Jacobs and team just walk away because it got too pricey for them? If you look at the numbers, I believe 10 or 11 times EBITDA. Not crazy expensive, but certainly more expensive than the discipline price you would see a Jacobs-run business want to pay.
Andy Cross: Sorry, about one times sales, as you mentioned, 10 to 11 times EBITDA. EBITDA's been down a little bit for the past year or so, but also because of the housing market, we know. But GMS, which by the way stands for Gypsum Management and Supply, runs 320 distribution centers selling things, including things like wallboard and ceilings, steel framings. It runs about 100 tool sales, rental, and service centers. Together, you're going to put together 1,200 locations, 8,000 trucks, making tens of thousand deliveries to job sites every day. What I like, Jason, as you mentioned, is these acquisitions for distribution scale matters, and this is a very fragmented business. I see this acquisition by Home Depot, this is a 5.5 billion dollar acquisition by Home Depot. Home Depot is a massive company, so Home Depot has about 45 billion of debt on the balance sheet. It's not going to add a ton more debt to the account. They have a $1.5 billion of cash, almost. I think from a management perspective, it's fairly attractive to Home Depot, and I can see why GMS would choose Home Depot versus QXO, even with Brad Jacobs' intelligence. But it does see when I look at the ability for Home Depot get a little bit more from every distribution node. I think it's attractive, and that multiple, as you mentioned, for Home Depot, I think, is not all that high. I think they're getting a good deal here.
Jason Hall: I think it probably works out so long as this remains a part of the strategy for Home Depot consolidating this fragmented distribution industry that's very different from its retail business. I will also make a prediction that Brad Jacobs and QXO made a big splash when they acquired Beacon Roofing as the first, looks like, $11 billion deal, so getting in the roofing business, one of the big roofing suppliers. My prediction is that we're going to see Home Depot and its distributor segment and Brad Jacobs' QXO going head to head on more acquisitions over the next 5-10 years, and probably both do well in consolidating because there's so much room to consolidate this market.
Andy Cross: That's the thing. It's so fragmented, so I think they can both be winners here. Brad Jacobs, if you look at his acquisition or look at his history of running companies with XPO and others, have done very well over the years. Like you said, he has this down to a science, the Beacon Roofing acquisition. That SRS acquisition by Home Depot, as you mentioned, for a little bit more than $18 billion, got them back into the distribution game, and so they're trying to cobble up that together. Both of these companies are trying to serve the contractor market, which is, as we mentioned, very fragmented, trying to increase the value of that network. For Home Depot, I think it's a good acquisition, I think, at a reasonable price, and I think Brad Jacobs was like, "Listen, there's going to be other opportunities. I'll let this one go. Home Depot, you can take this, and I'll focus my attention elsewhere." I do have a question, Jason, which is, if you think about either Home Depot stock or QXO stock, obviously GMS is going to be, if it all goes through, part of Home Depot, is there anyone that stands out as more attractive to you?
Jason Hall: There's my answer, and then there's the answer that people listening need to think about individually. For me, I think QXO is really attractive because I'm a big believer in Brad Jacobs and the track record, and the process when it comes to being disciplined and finding these industries to consolidate, starting from a really small size, this can be a massive compounder. Now, again, that's what I'm looking for. I think investors that are looking for maybe the higher floor of an industry dominant leader, like a Home Depot, that has a pretty solid dividend growth, and can continue to do well for investors over time, if you want something that's a little more stable, a little less volatile, then I think Home Depot's a pretty compelling investment right here. What about you? What do you think?
Andy Cross: Well, QXO at $14 billion, I think the upside is a lot higher. I own Home Depot, it's a large position in my portfolio. The stock hasn't done all that well over the past year or so. I think this is a nice bolt-on acquisition for them. Doesn't add a ton more goodwill to the balance sheet, maybe 2.5 billion or so on top of their 20 billion they have. I think it's reasonable. I think it's a decent price. I think they'll be able to get more out of it and continue to grow the GMS side of the business tied to SRS. It's just that Home Depot, like you said, is probably the high single digit per year grow or not, one that's going to light anything on fire going forward, Home Depot that is.
Jason Hall: Well, their leverage is there is going to be buying back shares. That's how you boost per share return there too.
Andy Cross: A hundred percent. Coming up next on Motley Fool Money, will F1 The Movie drive Apple stock higher? You're listening to Motley Fool Money. Brad Pitt's new movie F1, made by Apple Original Films, hit the theaters this weekend to positive reviews and decent amount of money, Jason. But here's my question, why is a $3 trillion company like Apple focused so much on making a film like F1, even with Brad Pitt.
Jason Hall: Because they can. They found the money on the couch cushions, and they saw it like a fun vanity project.
Andy Cross: They don't want to buy back more stock, and they've got plenty of places to invest that capital.
Jason Hall: In all seriousness, we're both being a little bit glib here, and it's Apple TV+, and their studios business has actually created some exceptionally high quality content. It's still a bit of an also ran, compared to the big players in the space, like the Netflixes of the world, but to me, I think it's a reminder that Apple is focusing on quality more necessarily than quantity as part of its strategy with streaming and media content real large.
Andy Cross: Does that mean the other ones are focused more on the quantity side, less on the quality side, do you think?
Jason Hall: I think a little bit both. I think all of them, there's a tension between the two, and it's where are you leveraging more toward. If you're a Netflix, for example, this is your entire business. You have to put out lots of content that's going to attract lots of people, and it's got to be very good quality. If you're an Apple, where does this fit in your entire ecosystem of things, and what you're looking to do maybe is a little bit different than say what Amazon is looking to do with Amazon Prime TV, or Amazon Prime Video, I should say. Where Apple does seem, if you look at the content that they've produced, certainly it doesn't have the volume that you see at some of these other large players, but what it does provide is an additional layer of stickiness to the platform.
Andy Cross: Do you think that they will up the quantity game to be more competitive? I think about this with Apple, right? Stories and reports are surfacing, 200 million to 300 million more on the entire cost to make this film, and Apple financed a chunk of change of that. Are you saying they have exclusive rights once it hits Apple TV? They'll be there. They splash marketing budgets all over the place. They had it in Apple stores. They had it featured in Apple Music, Apple Maps app. They had a big marketing push toward it, obviously, to show that they can be competitive in this space. I'm thinking like this, Apple generates about $400 billion or so in revenue. They generate, gosh, $100 billion in profits. Almost about a quarter or so of their business is tied to services. When I think about Apple building out that ecosystem, Jason, and the glue that they're putting together, as you mentioned, things like streaming to be competitive against likes of not just Netflix, but also the likes of Amazon, and the likes of YouTube, for a company that has middling growing, that continued growth in the services side of the business is important. I think that's one reason why they are now recognizing that because they generate such great returns on their investment, this is a place they can splash some capital.
Jason Hall: Netflix here, they want your eyes, they need you. They need as much as many people's time as they can get because this is their entire business. Amazon wants your wallet, and the bottom line is that nobody's going to cancel or subscribe to Amazon Prime just for prime video. It's a bolt-on thing that keeps you in the ecosystem and drives you there. Now, if you're Apple, think about some of the things they've done with content. One example is they own the rights to the Charlie Brown content. Think about Ted Lasso, shows like this. I think where Amazon wants your wallet and Netflix wants your eyes, Apple want your heart. They want you drawn to these things that you remember from your childhood. Brad Pitt headline products are very compelling. Ted Lasso, it's become a cultural touchstone. I think if they focus more on those, almost like the HBO model of the 2000s, of developing just a few really high quality contents that are strong enough to keep you attached, that's where this fits in with Apple, and where Apple can win with this. Whether this part of the business is necessarily profitable on its own basis, I think eventually they want to see that. But if it creates value for the entire ecosystem, I think that's the most important thing for Apple here.
Andy Cross: Is Apple attractive from a stock perspective? Again, I mentioned before, the growth has slowed. The stock has not been a super performer here, and now it sells in that 27-28 times earnings perspective, is with a lot of share buybacks, as you mentioned, in exceptionally profitable ways to invest, but still playing catch-up on the AI side. Is Apple attractive to you right now?
Jason Hall: Not at all. I love the business. I love the products. I'm a deep user of Apple products, and one of those people that signed up for Apple TV+ for Ted Lasso, and hasn't canceled it because there's so many other good unexpected programs that they have there. But the bigger concerns for me around a company like Apple's it's so fully valued, it's not growing. AI, I don't know that it's necessarily a concern right now, but at some point, they're trailing in that race for AI powered products, could potentially sneak up and hurt the company. They lack a real catalyst for the next leg of growth. Nothing is lined up to drive growth that would make 27, 28 times earnings or higher compelling to me. I think there's more risk of underperformance. I don't think investors are going to lose a ton of money here. There's a bigger risk of underperformance if you're making this a substantial portion of your portfolio.
Andy Cross: I agree. I think it's probably more in the money making category than adding to here. I'm an owner of it, and I'm just sitting on my shares, but not one that jumps to the top of my buy list right now, Jason. I do want to see a little bit more innovation from them, yet to come. I like the movies, but I do want to see innovation into the product cycle. That's a wrap for us today here on Motley Fool Money. Jason Hall, thanks for being here.
Jason Hall: Absolutely. This was fun. We'll do it again sometime soon.
Andy Cross: Here at Motley Fool Money, we love hearing your feedback. To be part of that feedback or just to ask a question, email us here at podcast@fool.com. That's podcast@fool.com. As always, people on the program may have interest in the stocks they talk about, and the Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what we do. All personal finance content follows Motley Fool editorial standards and is not approved by advertiser. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show notes. For all of us here at Motley Fool Money, thanks for listening. We'll see you tomorrow.
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Andy Cross has positions in Amazon, Apple, and Home Depot. Jason Hall has positions in Qxo. The Motley Fool has positions in and recommends Amazon, Apple, Home Depot, and Nike. The Motley Fool has a disclosure policy.
Nike is Back in the Race was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio


Business Insider
36 minutes ago
- Business Insider
Seeking Up to 11% Dividend Yield? Analysts Pick 2 Dividend Stocks to Buy
The stock markets hit a low in April, and have since shown a tremendous rebound – but can it last? That's the question investors are wrestling with now, and it seems they are getting some pointers from Barry Bannister, chief equity strategist at Stifel. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bannister believes that the stock rebound – fueled by the AI boom, and the rush of capital spending as companies moved to get ahead of tariffs during the first half of the year – is simply not sustainable, noting that the S&P 500 is trading at a historically high valuation. 'Valuation doesn't matter until it does,' Bannister says, and adds that he can see the S&P 500 index falling as low as 5,500, for a drop of nearly 15%. Despite this downbeat outlook, Bannister is not recommending that investors get out of the market. He's recommending, instead, that investors make defensive moves to seek protection from a turndown. That outlook will naturally push investors' attention toward high-yield dividend stocks. These represent the classic defensive play, and for good reason. Dividends offer investors a steady income stream, and high-yield dividends guarantee a sound return well above the rate of inflation. Against this backdrop, we've opened up the TipRanks database to take a look at two dividend stocks that the analysts are picking out as Buys. These are dividend stocks offering yields as high as 11%, a solid return by any standard. Let's give them a closer look. Ellington Financial (EFC) The first stock we'll look at here, Ellington Financial, is a REIT, a real estate investment trust. These companies operate through strategic investments, mainly in real properties, mortgages, and mortgage-related assets, in both the residential and commercial spheres. Ellington's particular strategy involves building a diverse investment portfolio, made up of both residential and commercial mortgage loans, along with residential and commercial mortgage-backed securities, as well as other assets, including consumer loans, collateralized loan obligations, and various mortgage-related and non-mortgage-related securities and derivatives. Ellington's main goal in building this portfolio is to generate returns for its stockholders – in the company's words, 'attractive risk-adjusted total returns.' Ellington's strategy is opportunistic, targeting remunerative investments, but the company takes a defensive posture as well, investing across a wide range of sectors to capitalize on disparate strengths in its portfolio and making risk management a key part of its activities. As of June 30 this year, Ellington Financial had a total of $16.1 billion in assets under management. This portfolio is managed by an experienced team – the company's portfolio managers average 30 years of industry experience. These features of Ellington's business, its focus on shareholder returns and the long experience of its management team, have helped the company to cement a reputation as a high-quality dividend payer. The company's dividend features a high yield, as well as a monthly payment schedule. The last declaration, made on August 7 for a September 30 payment, was for 13 cents per common share. That dividend annualizes to $1.56 per share and gives a powerful forward yield of 11.5%. In its 2Q25 financial report, Ellington listed its quarterly adjusted distributable earnings as $45 million, or 47 cents per share. This was more than enough to fully cover the dividend, which currently comes to 39 cents per quarter. Covering this stock for Piper Sandler, following the Q2 print, analyst Crispin Love laid out a clear case for investors to go long on EFC: 'Ellington posted a beat this quarter with strength in both its credit and Longbridge strategies. In April around the market volatility, Ellington saw opportunities to deploy capital in its core credit strategies and also saw attractive opportunities in securities. Following the volatility, EFC was able to complete six securitizations in the quarter, which is a record for the company. The company also experienced success from its loan originator platforms, and we would not be surprised to see more partnerships and equity stakes over the intermediate term. Specifically, if there is GSE reform it could limit Fannie and Freddie's footprint and provide opportunities for Ellington to grow further in the non-QM space which is an area of expertise. Management was positive on the forward earnings trajectory and continued coverage of the $0.39 dividend.' These comments back up Love's Overweight (i.e., Buy) rating, and his $14.50 price target implies a gain of 5.5% in the next 12 months. But with the dividend yield included the upside can reach 17%. (To watch Love's track record, click here) There are 7 recent analyst reviews on record for Ellington, and the 5-to-2 split, favoring Buys over Holds, supports a Moderate Buy consensus rating. The Street's average target of $14.25 is the same as Love's. (See EFC stock forecast) LPG) Our world runs on energy, and the next company on our list here, Dorian LPG, is a leading carrier of that energy. Dorian is an owner/operator of very large gas carriers, VLGC vessels, which are the largest ocean-going carriers of liquefied petroleum gas, an important fuel in the world economy. The core of Dorian's business is its fleet of ships. The company maintains a modern fleet of VLGCs, with the oldest ship dating back to 2007. Most of the company's vessels were launched much more recently, in 2015, and the newest vessels in the fleet were launched in 2023. The vessels have an average age of 8 years, and their aggregate carrying capacity is some 2.1 million cubic meters of LPG. Dorian owns 21 of its ships, and operates the others on charter agreements. Most of the ships in Dorian's fleet are flagged in the Bahamas, although several are flagged in Liberia, Madeira, or Panama. The company is headquartered in Connecticut and has offices in Copenhagen and Athens. The international office footprint, and varying flags, are also common on the world's oceangoing cargo carriers. Dorian finished its last quarter, fiscal 1Q26 (June quarter), with just over $278 million in cash and liquid assets. The company pays an irregular dividend, meaning it has no obligation to pay out, or to maintain dividend payments at any level; while this poses risks for investors, it also allows the company to adjust the dividend to keep them affordable. That said, Dorian has been paying out dividends since 2021, and has not missed a quarterly payment in that time. The most recent dividend, declared on August 1 for payment on the 27th, set the rate at 60 cents per share. This dividend annualizes to $2.40 per common share, and gives a forward yield of 8%. On the financial side, Dorian generated $84.2 million in total revenues during its fiscal first quarter, a total that was down 26% year-over-year and fell shy of analyst expectations by $2.3 million. Additionally, adj. EPS of $0.27 missed the Street's forecast by $0.34. Despite the weak report, Jefferies analyst Omar Nokta remains bullish on the stock, writing: 'Dorian reported softer than expected fiscal 1Q26 results mainly due to higher G&A and higher drydocking costs, and also slightly lower than expected revenues… We view this earnings miss as a one-off… VLGC spot rates have strengthened materially and are at 2025 highs, setting up a very strong upcoming result next quarter and potentially a higher dividend… The company remains dedicated to returning capital to shareholders, and its shares trade at a discount to our NAV valuation of $33.80/sh… Dorian is our top pick in the LPG space, and we remain constructive on the name.' The 5-star analyst rates LPG shares as a Buy, and gives them a price target of $35, pointing toward a one-year gain of 16.5%. (To watch Nokta's track record, click here) There are only 2 recent analyst reviews on file for Dorian, but both are positive, giving the stock its Moderate Buy consensus rating. The shares are priced at $30.06, and the $33 average price target implies a 10% upside potential on the one-year horizon. (See LPG stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.


Business Insider
an hour ago
- Business Insider
The Week That Was, The Week Ahead: Macro & Markets, August 17, 2025
Everything to Know about Macro and Markets Stocks ended the week on a soft note, still managing to lock in back-to-back weekly gains. The S&P 500 (SPX) rose 0.94% for the week, and the Nasdaq-100 (NDX) inched up 0.43%. The Dow Jones Industrial Average (DJIA) was the standout, delivering a weekly gain of 1.74%. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. A Week of Contrasts After a red Monday, all three major indexes reached all-time highs on Tuesday. This followed in-line CPI data, which bolstered bets that the Fed would deliver its first rate cut of 2025 in September – traders have priced in nearly a 100% chance of a 25-bps easing. Stocks extended gains on Wednesday: the S&P 500 and Nasdaq hit new ATHs again amid remarks from Treasury Secretary Scott Bessent urging a 50-bps cut based on downward revisions in payroll data. Wall Street analysts began forecasting up to three cuts this year, citing a softer labor market, limited tariff pass-through to consumer prices, and the appointment of Trump's temporary Fed board pick. But those forecasts were questioned Thursday when PPI, which tracks wholesale price trends, came in hotter than expected, denting sentiment and clouding the Fed outlook. Other economic reports pulled markets in opposing directions: July's industrial production was lackluster – although not recession-bellwether weak – while retail sales beat forecasts, underscoring resilient consumer demand despite high borrowing costs. Meanwhile, the UoM consumer sentiment unexpectedly slipped and inflation expectations rose, muddying the outlook for Fed cuts in September. On Friday, the Dow's gains were dominated by UnitedHealth's surge following Berkshire Hathaway's disclosure of a large stake in the embattled healthcare giant. Meanwhile, the S&P 500 and Nasdaq's advances were tempered by tech weakness amid cautious corporate outlooks and persistent tariff concerns, particularly in semiconductors. This week featured leadership rotation: healthcare and small-caps rose, while semiconductors and tech lagged under the weight of inflation and trade worries. With mixed inflation and consumer data re-injecting uncertainty into the Fed policy outlook, all eyes now turn to Jackson Hole. Jerome Powell's speech on August 22 is the marquee event, expected to instantly influence markets. A dovish tone could broaden the rally, boosting small caps, rate-sensitive areas, and tech. A hawkish stance – highlighting inflation risks or caution – could trigger sharp corrections and volatility, especially in growth and rate-sensitive sectors. Adaptability, Profitability, and Capex Economic data remains mixed – but corporate signals are broadly bullish, despite overbought pockets and uneven strength. As Benjamin Graham famously said, 'in the short run, the market is a voting machine but in the long run, it is a weighing machine.' Prices may swing on sentiment or episodic events, but over time, earnings growth is what ultimately matters. On that front, Q2 2025 earnings have been compelling: over 90% of companies have reported, with average EPS growth near 11% year-over-year – versus expectations of 3-4% at the quarter's start. This follows a similar pattern seen in Q1 season. In the second quarter, 84% beat expectations, surprising by an average of 9%. U.S. companies' adaptability – particularly in counteracting tariff shocks – is helping shield both the economy and equity markets. Notably, S&P 500 forward 12-month EPS estimates are now at record highs, driven largely by tech megacap profitability and reinvestment. AI capex alone has contributed more to GDP growth in H1 2025 than consumer spending. While over the long term, consumer demand has been the undisputed engine of growth – megacaps' AI and cloud investment plans signal continued acceleration of their role in fueling the expansion. The sterling Q2 earning-growth results have broadly dispelled investor fears over trade policies weighing on the economy and corporate performance. FactSet reports that 'recession' mentions in earnings calls dropped nearly 70% from Q1 2025, hitting their lowest levels since 2005. Polymarket's 2025 recession odds plunged from over 65% in May to 12%, signaling there's no longer a belief that levies on imports mean a recession is imminent. Tariffs still get airtime, even if much less than in Q1 – but the C-suite and market participants now see them as manageable. Factors such as lower energy prices and decelerating housing-related inflation are further diluting the tariff impact. Strategists now expect any tariff impact on inflation to be delayed and muted, with economic growth holding relatively firm. Stocks That Made the News ▣ UnitedHealth (UNH) soared over 22% on the week after Berkshire Hathaway ($BRK.B) disclosed a new stake in the beaten-down healthcare provider. Warren Buffett's conglomerate acquired 5.04 million UNH shares valued at $1.57 billion. ▣ Applied Materials (AMAT) plunged 13% despite delivering record performance last quarter, as the chip equipment provider offered weaker-than-expected guidance amid weak China demand, stalled export license approvals, and uneven orders. Despite the near-term challenges, the company remains optimistic about mid-single-digit growth for fiscal 2025, driven by investments in U.S. manufacturing and advancements in semiconductor technology. ▣ Intel (INTC) was on the winning side of the semi trade, popping by over 22% on the week following reports that the Trump administration was mulling the potential for the government to take a stake in the embattled company to aid domestic chip manufacturing expansion. ▣ Palantir Technologies (PLTR) declined after Andrew Left, head of short-selling firm Citron Research, said he was betting against the company in light of its lofty valuation, which he called 'absurd.' ▣ Amazon (AMZN) rallied as analysts applauded analysts applauding its expansion into free same-day grocery delivery nationwide for Prime members. Evercore ISI said that this expansion deepens Amazon's customer engagement by strengthening a high-frequency purchase category into the Prime ecosystem, increasing stickiness and customer lifetime value. ▣ Oracle (ORCL) also bucked the down trend on Friday, rallying on news of expanded partnership with Alphabet's (GOOGL) Google Cloud. Under the collaboration, Oracle will integrate Google's Gemini AI models into Oracle Cloud Infrastructure (OCI). This allows Oracle's enterprise customers to access Google's Gemini AI capabilities – including multimodal understanding, coding assistance, and workflow automation – via OCI services, enhancing productivity and workflow automation. The deal – similar to one that Oracle struck with Elon Musk's xAI back in June – is expected to significantly broaden Oracle's AI offerings, advancing its strategy of offering a menu of AI options rather than trying to push its own technology exclusively. The Q2 2025 earnings season is winding down, but several notable releases are still scheduled for this week. These include: Palo Alto Networks (PANW), Home Depot (HD), Medtronic (MDT), Keysight Technologies (KEYS), TJX Companies (TJX), Lowe's (LOW), Analog Devices (ADI), Target (TGT), Walmart (WMT), Intuit (INTU), Workday (WDAY), and Ross Stores (ROST).